CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows, general and gastrointestinal surgeons and other allied healthcare professionals involved in the treatment of hepatocellular carcinoma.
  
  LEARNING OBJECTIVES

  • Evaluate recently presented clinical research findings to determine their effect on the current management of localized or advanced hepatocellular carcinoma (HCC).
  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic HCC.
  • Appreciate Phase III data leading to the FDA approvals of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how they can be optimally integrated into patient care.
  • Evaluate the rationale for and available data with anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for HCC to determine the current role of these novel regimens.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Recall recently presented clinical trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy for patients with HCC and a high risk of recurrence after curative resection or ablation, and consider the potential role of this strategy in clinical practice.
  • Review available and emerging data with agents and strategies currently in clinical testing for HCC, and appropriately refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ghassan Abou-Alfa, MD, MBA
  Attending
  Memorial Sloan Kettering Cancer Center
  Professor
  Weill Cornell Medical College at Cornell University
  Adjunct Professor
  Trinity College Dublin (Ireland)
  New York, New York
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Autem Therapeutics, Berry Genomics, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, FibroGen Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Neogene Therapeutics, Novartis, Servier Pharmaceuticals LLC, Tempus, Thetis Pharmaceuticals, Vector Pharma, Yiviva; Contracted Research: Agenus Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Puma Biotechnology Inc, QED Therapeutics, Yiviva; Nonrelevant Financial Relationship: Parker Institute for Cancer Immunotherapy.
  
  Daneng Li, MD
  Associate Professor
  Department of Medical Oncology and Therapeutics Research
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Consulting Agreements: Coherus BioSciences, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Merck, Servier Pharmaceuticals LLC, TerSera Therapeutics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Brooklyn ImmunoTherapeutics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: September 2023
  Expiration date: September 2024